Safer Vectors and Strategies For Gene Therapy

更安全的基因治疗载体和策略

基本信息

  • 批准号:
    7254043
  • 负责人:
  • 金额:
    $ 5.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-01 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Retroviral vectors are excellent tools for the stable delivery of gene products into cells of therapeutic interest. However, use of these vectors in a clinical setting has recently been shown to be problematic. In a gene therapy trial for the correction of Severe Combined Immune Deficiency (SCID), two patients, out of eleven, developed T-cell leukemia as a direct result of an integrated retroviral vector. In an effort to prevent undesirable outcomes in future gene therapy trials, a primary goal of this study is the development and testing of novel vectors and strategies aimed at increased safety without the loss of effectiveness. New vectors will be developed that are less likely to lead to insertional mutagenesis while still retaining the therapeutic benefits. This will require the engineering of DMA elements with enhancer-blocking activity to inhibit transactivation of adjacent genes in genomic DMA. Incorporation of a regulatable suicide gene, which could be activated in the case of an adverse outcome, will provide an additional safety feature. Lastly, the vectors and strategies discussed above along with the use of limited numbers of genetically modified cells will be tested for their ability to rescue a genetic defect in a murine model of immunodeficiency. This project is aimed at tempering efficacy with safety in producing the safest, most potent retroviral vectors for use in human gene therapy trials.
描述(由申请人提供):逆转录病毒载体是将基因产物稳定地传递到治疗目的细胞的优秀工具。然而,在临床环境中使用这些载体最近被证明是有问题的。在一项纠正严重联合免疫缺陷(SCID)的基因治疗试验中,11名患者中有2名患者直接由于综合逆转录病毒载体而患上了t细胞白血病。为了防止在未来的基因治疗试验中出现不良后果,本研究的主要目标是开发和测试新的载体和策略,旨在提高安全性而不丧失有效性。新的载体将被开发,不太可能导致插入突变,同时仍然保留治疗的好处。这将需要具有增强子阻断活性的DMA元件的工程来抑制基因组DMA中邻近基因的转激活。纳入可调节的自杀基因(在出现不良结果时可被激活)将提供额外的安全功能。最后,上述讨论的载体和策略以及有限数量的转基因细胞的使用将在小鼠免疫缺陷模型中测试它们拯救遗传缺陷的能力。这个项目的目的是在保证有效性的同时保证安全性,生产最安全、最有效的逆转录病毒载体,用于人类基因治疗试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE J MURPHY其他文献

GEORGE J MURPHY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE J MURPHY', 18)}}的其他基金

UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES
了解系统性淀粉样蛋白疾病中的肝脏蛋白质稳态
  • 批准号:
    10598011
  • 财政年份:
    2020
  • 资助金额:
    $ 5.2万
  • 项目类别:
UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES
了解系统性淀粉样蛋白疾病中的肝脏蛋白质稳态
  • 批准号:
    10376880
  • 财政年份:
    2020
  • 资助金额:
    $ 5.2万
  • 项目类别:
UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES
了解系统性淀粉样蛋白疾病中的肝脏蛋白质稳态
  • 批准号:
    10052855
  • 财政年份:
    2020
  • 资助金额:
    $ 5.2万
  • 项目类别:
UNDERSTANDING HEPATIC PROTEOSTASIS IN SYSTEMIC AMYLOID DISEASES
了解系统性淀粉样蛋白疾病中的肝脏蛋白质稳态
  • 批准号:
    10215499
  • 财政年份:
    2020
  • 资助金额:
    $ 5.2万
  • 项目类别:
Mechanisms of cis-acting HbF regulation in sickle cell anemia
镰状细胞性贫血中顺式作用 HbF 调节机制
  • 批准号:
    9926298
  • 财政年份:
    2017
  • 资助金额:
    $ 5.2万
  • 项目类别:
Defining the Role of the AHR in Blood Cell Specifications
定义 AHR 在血细胞指标中的作用
  • 批准号:
    9193079
  • 财政年份:
    2016
  • 资助金额:
    $ 5.2万
  • 项目类别:
TARGETING ENDOGENOUS SIGNALING PATHWAYS TO AMELIORATE SYSTEMIC AMYLOIDOSES
靶向内源信号传导途径以改善系统性淀粉样变
  • 批准号:
    8752486
  • 财政年份:
    2014
  • 资助金额:
    $ 5.2万
  • 项目类别:
TARGETING ENDOGENOUS SIGNALING PATHWAYS TO AMELIORATE SYSTEMIC AMYLOIDOSES
靶向内源信号传导途径以改善系统性淀粉样变
  • 批准号:
    9304206
  • 财政年份:
    2014
  • 资助金额:
    $ 5.2万
  • 项目类别:
TARGETING ENDOGENOUS SIGNALING PATHWAYS TO AMELIORATE SYSTEMIC AMYLOIDOSES
靶向内源信号传导途径以改善系统性淀粉样变
  • 批准号:
    9105178
  • 财政年份:
    2014
  • 资助金额:
    $ 5.2万
  • 项目类别:
Safer Vectors and Strategies For Gene Therapy
更安全的基因治疗载体和策略
  • 批准号:
    7093539
  • 财政年份:
    2005
  • 资助金额:
    $ 5.2万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.2万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了